In the U.S., May is observed as Mental Health Awareness Month, a tradition that goes back to 1949. About 60 million American adults live with some form of mental illness, ranging from mild anxiety and depression to more severe psychiatric conditions, according to reports.
The theme for this year is "More Good Days, Together," focusing on community support.
Shifting focus to the regulatory landscape, the May FDA calendar appears relatively light.
The upcoming regulatory milestones include a potential label expansion of argenx SE's VYVGART, and an additional indication for Daiichi Sankyo Company and AstraZeneca plc's cancer therapy Enhertu. Also awaiting FDA decisions in May are Eisai's supplemental Biologics License Application for Leqembi iqlik, and a supplemental application from MannKind evaluating Afrezza use in pediatrics.
Let's take a look at the biotech stocks facing the FDA decisions in May 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.